Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer
Total Page:16
File Type:pdf, Size:1020Kb
Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer. Item Type Article Authors Tokhanbigli, Samaneh;Asadirad, Ali;Baghaei, Kaveh;Piccin, Andrea;Yarian, Fatemeh;Parsamanesh, Gilda;Hashemi, Seyed Mahmoud;Asadzadeh Aghdaei, Hamid;Zali, Mohammad Reza DOI 10.2147/ITT.S245913 Journal ImmunoTargets and therapy Rights © 2020 Tokhanbigli et al. Download date 09/10/2021 02:13:25 Link to Item http://hdl.handle.net/10147/629662 Find this and similar works at - http://www.lenus.ie/hse ImmunoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer This article was published in the following Dove Press journal: ImmunoTargets and Therapy Samaneh Tokhanbigli1,* Introduction: Albeit early stage gastrointestinal (GI) carcinomas have a good prognosis if Ali Asadirad2,* treated with surgery, diagnosis is often confirmed at a late stage and efficacious drugs are Kaveh Baghaei1 lacking. Recent progress in immune-based therapies has focused on dendritic cells (DCs), fi Andrea Piccin3,4 aiming to elicit tumor-speci c responses by inducing immunological memory. Our previous Fatemeh Yarian5 microarray study indicated that a biomarker, termed lymphocyte antigen-6E (LY6E), is commonly overexpressed in two potentially lethal GI cancers: those of colon and stomach. Gilda Parsamanesh1 In this study, we examined the antigenic potency of LY6E in stimulating DCs. Seyed Mahmoud Hashemi 6 1 Methods: Following isolation, differentiation, and maturation of mononuclear cells, DCs Hamid Asadzadeh Aghdaei were pulsed with LY6E peptide, a protein related to major histocompatibility complex 7 Mohammad Reza Zali (MHC) class I/II. Subsequently, DCs were co-cultured with mouse splenocytes to assess 1Basic and Molecular Epidemiology of antigen-specific T-cell proliferation. Elucidated cytotoxic T-lymphocyte responses were Gastrointestinal Disorders Research assessed using subcutaneous colorectal murine tumor models. For personal use only. Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Results: Our in vitro results suggest that DCs loaded with LY6E peptide antigen are capable Beheshti University of Medical Sciences, of stimulating and inducing proliferation of murine T-cells. Furthermore, our in vivo results 2 Tehran, Iran; Department of Immunology, demonstrate that LY6E peptide has a substantial impact on provoking immune responses Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; against induced colon cancer in mice. 3Haematology Department, Our Lady’s Discussion: In conclusion, based on the overexpression of LY6E in colorectal, gastric, and Children’s Hospital, Dublin, Ireland; pancreatic cancers, the role of this peptide should be further investigated with a goal of 4Department of Internal Medicine V, University of Innsbruck, Innsbruck, Austria; developing new therapies for these challenging diseases. 5 Department of Biotechnology, School of Keywords: dendritic cell, colorectal cancer, LY6E, dendritic cell tumor-associated antigen Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, therapy Tehran, Iran; 6Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ImmunoTargets and Therapy downloaded from https://www.dovepress.com/ by 193.32.126.161 on 10-Jun-2021 7Gastroenterology and Liver Diseases Introduction Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Gastrointestinal (GI) cancers are a leading cause of death, with increasing incidence Beheshti University of Medical Sciences, reported worldwide.1,2 Several therapeutic strategies have been developed, includ- Te h r a n , I r a n ing chemotherapy, surgery, and radiation therapy as well as immune-directed *These authors contributed equally to this therapies such as monoclonal antibodies.3–8 Antigen-presenting cells (APCs) such work as dendritic cells are the primary coordinators of the innate and adaptive immune Correspondence: Kaveh Baghaei responses (humoral or antigen-specific CD8+ T-cells, respectively) that generate Research Institute of Gastroenterology cytotoxic T-lymphocytes (CTLs).9 and Liver Disease (RIGLD), Aerabi St, Yemen St, Chamran Highway, Tehran, Iran Dendritic cells play a crucial role in introducing tumor-associated antigens Tel +98 9123592868 fi Email [email protected] (TAA) to naïve T-cells in lymph nodes. The induction of speci c T-cells against TAA peptides is known as the “antigen presentation” phase. Studies have shown Andrea Piccin Haematology Department, Our Lady’s that vaccines produced on the basis of TAA-peptides provide robust and effective Children’s Hospital, Dublin, Ireland CTL responses.10,11 It is imperative, therefore, to identify an appropriate tumor Tel +353 89 6082831 Email [email protected] antigen for the design of DC tumor-based vaccines, aimed at preventing tumor submit your manuscript | www.dovepress.com ImmunoTargets and Therapy 2020:9 95–104 95 DovePress © 2020 Tokhanbigli et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ – http://doi.org/10.2147/ITT.S245913 terms.php and incorporate the Creative Commons Attribution Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) Tokhanbigli et al Dovepress development and inducing tumor regression. It may also of any experiments, to allow adaptation to environmental be possible to design a multi-functional vaccine if conditions. All experiments performed were approved by a common antigen can be identified across several cancers. the Ethics Committee of the Research Institute for Multi-purpose therapeutic anti-cancer strategies could Gastroenterology and Liver Diseases (RIGID) and Shahid be developed by identifying common actors that partici- Beheshti Medical University (SBMU) (Code of Ethics: IR. pate in metabolic pathways involved in the development of SBMU.MSP.REC.1395.401). GI cancers. One of the common players that has been identified is lymphocyte antigen-6E (LY6E), a protein Peptide Prediction and Synthesis that is highly expressed in colorectal, gastric, and pancrea- Immune Epitope Database and Analysis Resource (IEDB)22 tic cancers. LY6 superfamily proteins are found in leuko- was used as a prediction tool for Major Histocompatibility cytes and were first observed in activated T-cells.12–16 Complex (MHC) Class I and Class II binding sites and for Previous studies have identified LY6E as a common sur- the design of potential T-cell binding epitopes. Since part of face marker in gastric and colorectal cancers17 as well as the protein in its linear form binds to MHCs to provoke pancreatic cancers.18 Additionally, investigation of both the T-cell responses, epitope mapping was carried out for Gene Expression Omnibus (GEO) database and the mouse MHC classes. Amongst all peptides evaluated, Georgetown Database of Cancer (G-DOC) has revealed that those with the highest ranked score (correlated with highest in comparison to adjacent tissues, LY6E had increased levels predicted response in provoking T-cells) were selected. of expression in many cancers. Furthermore, worse overall The peptide selected for this study (LY6E) with survival has been directly linked to LY6E over-expression.15,19 sequence of EKDHYCITLSAAAGF was designed for The LY6E protein is recognized to be of particular impor- Mouse MHCI-II H2-IAb and was synthesized by Shine tance in cell-cell adhesion and signal transduction through Gene Molecular Biotech (Shanghai, China), provided at T-cell receptors and T-cell development.19 The significance 75% purity. Peptides were dissolved in Dimethyl sulfoxide (DMSO) and kept at −80°C until use. For personal use only. of LY6E in tumor growth is postulated to involve modulation of the PTEN/PI3K/Akt/HIF-1 axis,20 a survival mechanism adopted by tumors in hypoxic environments. Antibodies and Reagents Promising results have been obtained by exploring the Fluorochrome-conjugated (FACS) antibodies were used to use of antibody-drug conjugates (ADCs). In vitro and characterize the immature and mature DCs and T-cell expres- fl in vivo models of many cancers such as breast and ovar- sion markers. CD40, CD14, CD11c, and CD8 ( uorescein ian, pancreatic, non-small cell lung cancer (NSCLC), and isothiocyanate-conjugated (FITC)), CD4, CD80, CD86, and lymphoma demonstrated that ADCs targeting LY6E show MHC II (PE-conjugated (Phycoerythrin)), and CD3 (PreCP- promising clinical activity, with high expression of LY6E Vio700) were all obtained from eBioscience (Germany). in cancer cells compared to their adjacent tissues.21 Culture reagents and cytokines used for in vitro generation We report an in vivo study on the use of LY6E for and maturation of DCs consisted of RPMI-1640 medium ImmunoTargets and Therapy downloaded from https://www.dovepress.com/ by 193.32.126.161 on 10-Jun-2021 pulsing DCs by “reverse immunology”, in which the (Biosera, cat no: LMR1638, France) supplemented